Neuphoria Therapeutics Inc. has successfully regained compliance with the Nasdaq’s Minimum Bid Price Requirement, the company announced Monday. The pharmaceutical firm, which is listed on the Nasdaq Stock Market under the ticker symbol NASDAQ:NEUP, maintained a closing bid price of at least $1.00 per share for ten consecutive business days, from December 24, 2024, to January 8, 2025.
The stock currently trades at $3.20, significantly above the compliance threshold, though it remains well below its 52-week high of $10.50. According to InvestingPro analysis, the stock appears undervalued at current levels.
The compliance notice from Nasdaq followed a previous warning that Neuphoria Therapeutics had fallen below the required minimum bid price. In July 2024, the company received a deficiency letter from Nasdaq due to its American Depositary Shares not meeting the $1.00 minimum bid price over a 30-day period.
The re-domiciliation of the company from Australia to Delaware, which took effect on December 24, 2024, appears to have been a pivotal move in restoring compliance. InvestingPro data shows the stock has faced significant pressure, with a -52.34% return over the past six months.
The issue has now been resolved, and the matter is considered closed, according to the company’s statement based on the press release. This development is significant for Neuphoria Therapeutics, as maintaining compliance with Nasdaq’s listing requirements is crucial for the company’s continued presence on the exchange. The company maintains a healthy financial position with a current ratio of 3.3, and InvestingPro assigns it a “Fair” overall Financial Health Score.
Neuphoria Therapeutics also included forward-looking statements in their report, cautioning that while they have regained compliance, there are risks and uncertainties that could affect their ability to maintain their Nasdaq listing in the future. The company emphasized that these forward-looking statements are not guarantees of future performance and that actual results could differ materially due to various factors.
Investors and stakeholders are advised to take note of the company’s compliance status and the inherent uncertainties that come with forward-looking statements. Neuphoria Therapeutics’ filings with the Securities and Exchange Commission can provide additional insight into the company’s financial health and market standing. For deeper analysis and exclusive insights into Neuphoria’s valuation and growth prospects, investors can access comprehensive financial metrics and expert analysis through InvestingPro.
In other recent news, Bionomics Limited has announced a shareholder meeting to vote on the proposed re-domiciliation of the company to the United States. This strategic move would transition Bionomics into Neuphoria Therapeutics Inc., a newly incorporated company in Delaware. Bionomics has also received a milestone payment of AUS$1 million from Carina Biotech as part of an exclusive worldwide license agreement for BNC101, a monoclonal antibody targeting cancer stem cell antigen LGR5.
The company has initiated phase 3 trials for its lead drug candidate, BNC210, developed for the treatment of social anxiety disorder and post-traumatic stress disorder. Bionomics has seen a significant change in its board with the resignation of Aaron Weaver, a decision not associated with any disagreements within the company. In collaboration with Merck (NS:) & Co., Inc, Bionomics is developing drugs for cognitive dysfunction in Alzheimer’s disease and other central nervous system conditions.
Despite receiving a Nasdaq delisting notice due to non-compliance with the minimum bid price requirement, Bionomics has secured significant funding, potentially up to $70 million, expected to sustain operations into the third quarter of 2025. This funding agreement has been endorsed by H.C. Wainwright, which has maintained its Buy rating for Bionomics. These are the recent developments for Bionomics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
